Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Donald Trump’s Mar-a-Lago residence raided by FBI agents
    • Xi Jinping grasps ‘knife’ of internal security to complete grip on power
    • China extends military drills around Taiwan and ramps up propaganda
    • Norway set to curb electricity exports in blow to European energy supplies
    • Tech sector tax windfall shores up Ireland’s economy against recession
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Carlyle’s chief executive resigns after breakdown in contract talks
      • BioNTech and Pfizer to begin vaccine clinical trial for new Covid variants
      • Corporate America fumes over Biden’s tax and climate package
      • London’s ‘magic circle’ law firms make renewed bid to crack US
      • Investors sell stakes in buyout funds at a record pace
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
      Most Read
      • Live news updates from August 8: China continues military drills around Taiwan, Falling tech stocks send SoftBank to $23.3bn loss
      • Investors sell stakes in buyout funds at a record pace
      • Energy companies urge UK to detoxify gas exports to EU
      • Live news updates: Russian oil flow halted through Druzhba pipeline to central Europe
      • US stocks tick lower as traders assess outlook for rate rises
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Dangerous fatalism about a US-China war
      • Bad news for Big Tech
      • Where have all the UK’s self-employed gone?
      • Demography is not destiny
      • Embattled Trump fans dig in at Michigan county fair
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Can a city be redesigned for the new world of work?
      • Brompton’s Will Butler-Adams: ‘People have no idea what goes into a product. That’s not a good thing’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Gentle parenting, yes or no? FT readers respond
      • Five of the best places in London for ‘free-from’ pastries
      • 10 reasons to love London this August
      • The anxious generation — what’s bothering Britain’s schoolchildren?
      • The best new watersports gear
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Your guide to a disrupted world

    Start a 4-week trial

    BioNTech

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 8 August, 2022
      Covid-19 vaccines
      BioNTech and Pfizer to begin vaccine clinical trial for new Covid variants

      German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations

    • Tuesday, 19 July, 2022
      LexCovid-19 vaccines
      Covid-19 vaccines: shape-shifting virus puts agile manufacturers at an advantage Premium content

      The latest strains have spread fast and governments are trying to catch up

    • Tuesday, 5 July, 2022
      CureVac GmbH
      CureVac sues BioNTech over mRNA patents

      Pharma group seeks compensation from Covid vaccine maker for alleged IP infringements

    • Saturday, 25 June, 2022
      Covid-19 vaccines
      BioNTech/Pfizer say Omicron-targeting boosters elicit strong immune response

      New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain

    • Saturday, 18 June, 2022
      Covid-19 vaccines
      BioNTech chief calls for speedy ruling on Covid vaccines that target latest strains

      ‘Time is ticking’ as studies suggest original Omicron jabs may not offer strong protection against sub-variants

    • Wednesday, 15 June, 2022
      Covid-19 vaccines
      FDA advisory panel backs Covid-19 vaccines for children under 5

      US prepares to roll out jabs to last age group without access once regulatory approval is received

    • Tuesday, 14 June, 2022
      The Big Read
      BioNTech’s second act: can it transform the fight against cancer?

      The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven

    • Wednesday, 8 June, 2022
      Lex
      BioNTech/pancreatic cancer: mRNA jabs may tame a savage disease Premium content

      German biotech’s promising early-stage results make it a sought-after partner

    • Monday, 9 May, 2022
      Covid-19 vaccines
      BioNTech beats forecasts on back of Covid vaccine demand

      German biotech maintains guidance but prepares for fall in sales because of jab oversupply

    • Tuesday, 5 April, 2022
      Pfizer Inc
      Chief executives of mRNA vaccine groups earned $100mn in pandemic pay

      Remuneration at the three big jab makers reflects surge in value of share options

    • Wednesday, 30 March, 2022
      BioNTech to return almost €2bn to shareholders after Covid vaccine success

      German biotech plans to boost R&D spending by 50% as quarterly earnings beat forecasts

    • Wednesday, 16 February, 2022
      Covid-19 vaccines
      Children aged 5 to 11 to be offered Covid vaccine in England

      Johnson government announces plan after similar moves in Scotland and Wales

    • Tuesday, 25 January, 2022
      Covid-19 vaccines
      BioNTech/Pfizer start clinical trial of Omicron vaccine

      First human study of variant-specific jab by big western drugmaker could prompt shift in manufacturing

    • Wednesday, 12 January, 2022
      Coronavirus pandemic
      BioNTech and AI start-up develop tool to predict high-risk coronavirus variants

      Hopes early warning system will give policymakers and vaccine producers more time to address health risks

    • Wednesday, 5 January, 2022
      Pfizer Inc
      Pfizer and BioNTech team up to develop mRNA-based shingles vaccine

      Drugmakers set to take on GSK as they aim to replicate Covid jab success

    • Sunday, 26 December, 2021
      German economy
      German city reaps tax windfall from BioNTech’s Covid vaccine success

      Long the poor relation to Frankfurt, Mainz aims to cash in on ‘priceless advertising’ offered by biotech group

    • Wednesday, 8 December, 2021
      Covid-19 vaccines
      Pfizer says three vaccine doses offer protection against Omicron

      Preliminary research suggests two shots show significantly reduced effectiveness against new coronavirus variant

    • Wednesday, 1 December, 2021
      ExplainerCovid-19 vaccines
      Will Covid vaccines have to be updated for Omicron?

      Drugmakers are stress-testing existing jabs while preparing new formulas

    • Tuesday, 30 November, 2021
      Covid-19 vaccines
      Vaccine makers split on protection against Omicron variant

      WHO says differing predictions from Oxford, BioNTech and Moderna are ‘premature’

    • Monday, 29 November, 2021
      LexCovid-19 vaccines
      Omicron vaccines: booster shots will boost the mRNA pioneers Premium content

      Combating coronavirus could end up resembling a game of whack-a-mole

    • Tuesday, 9 November, 2021
      BioNTech lifts revenue forecast as Covid vaccine orders climb

      German biotech expects to hit €17bn in sales and produce 3bn jabs this year

    • Thursday, 4 November, 2021
      News in-depthCovid-19 vaccines
      US battles to sell parents on benefits of ‘kid-sized’ jabs for children

      Hesitancy high as regulators authorise BioNTech/Pfizer Covid-19 vaccine for 5 to 11 year olds

    • Friday, 29 October, 2021
      Covid-19 vaccines
      FDA approves BioNTech/Pfizer jab for 5 to 11-year-olds

      US expected to become first country to authorise vaccine for younger children

    • Tuesday, 26 October, 2021
      BioNTech to open Africa’s first mRNA manufacturing plant

      Rwanda and Senegal agreement a big step in plans to produce Covid jabs on the continent

    • Monday, 25 October, 2021
      Covid-19 vaccines
      Covid vaccines associated with rare neurological complications, says study

      Researchers emphasise that adverse events following Pfizer and AstraZeneca jabs are extremely rare

    Previous page You are on page 1 Next page

    Be part of FT Community

    Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

    FT LiveGlobal Pharma and Biotech SummitDriving Investment and Innovation in Life Sciences
    Monday, 7th NovemberRoyal Lancaster Hotel, London
    Learn more about FT Community

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Community
      • FT Live
      • FT Forums
      • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In